Studies to Understand the Stability and Liabilities of Legumain-cleavable Antibody-drug Conjugates
Year: 2025
Type: dissertation
Abstract: Antibody-drug conjugates (ADCs) offer targeted drug delivery of potent cytotoxic payloads, minimizing systemic toxicity. However, the stability of the linker is integral to ensure that there is minimal off-target payload release and little systemic toxicity. This study analyzes the physical and biological stability of our new legumain-cleavable vs traditional cathepsin-cleavable antibody-drug conjugates (ADCs), with a focus on hydrophobicity, thermal stability, aggregation, and biological payload release. Our findings indicate that decreased hydrophobicity of the legumain-cleavable ADCs compared to cathepsin-cleavable ADCs is correlated with decreased aggregation (predicting lower uptake by liver macrophages and therefore slower clearance and less systemic toxicity) and lower amounts of off-target payload release (predicting less systemic toxicity). Exatecan ADCs employing the mcGlyAsnAsn(GABA)_Exatecan linker-payload had the greatest amount of stability across the experiments. However, our studies suggest that both legumain-cleavable and cathepsin-cleavable ADCs are susceptible to cleavage by proteases secreted by macrophages present in the tumor microenvironment; legumain-cleavable ADCs offer no improvements in this regard. Overall, this study provides valuable insights into the development of ADCs with enhanced stability and reduced off-target toxicity.
Author: Yi, Michele
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7110578961
